Related Experiment Video
Updated: Jun 19, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
[Diagnosis and treatment of rare mixed prostatic carcinoma]
Lu Yi1, Luo-Yan Yang, Yin-Huai Wang
1Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Objective:
To discuss the diagnosis and treatment of rare mixed prostatic carcinoma.
Methods:
We retrospectively analyzed the clinical data of 6 cases of mixed prostatic tumor confirmed by surgery or transrectal ultrasound guided prostate biopsy, and reviewed the related literature.
Results:
Three of the patients (2 with mixed small cell carcinoma and adenocarcinoma and 1 with adenosquamous carcinoma of the prostate) underwent palliative transurethral electrovaporization of the prostate (TUVP) and endocrine therapy, but all died within 7 - 10 months. The other 3 (2 with adenosquamous carcinoma and 1 with carcinosarcoma of the prostate) received cystoprostatectomy, urinary diversion, pelvic lymphadenectomy and radiation therapy, and survived for more than 12 months, with 2 of them still under the follow-up observation.
Conclusion:
Mixed prostatic carcinoma behaves aggressively with poor prognosis, of which the diagnosis relies on meticulous pathological examination and immunohistochemical techniques, and the most effective treatment is radical surgery.
